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Abstract
Drug combination trials are increasingly common nowadays in clinical research. However,
very few methods have been developed to consider toxicity attributions in the dose escalation
process. We are motivated by a trial in which the clinician is able to identify certain toxic-
ities that can be attributed to one of the agents. We present a Bayesian adaptive design in
which toxicity attributions are modeled via Copula regression and the maximum tolerated dose
(MTD) curve is estimated as a function of model parameters. The dose escalation algorithm
uses cohorts of two patients, following the continual reassessment method (CRM) scheme,
where at each stage of the trial, we search for the dose of one agent given the current dose of
the other agent. The performance of the design is studied by evaluating its operating charac-
teristics when the underlying model is either correctly specified or misspecified. We show that
this method can be extended to accommodate discrete dose combinations.
Keywords: Attributable toxicity; Cancer phase I trials; Continual reassessment method; Cop-
ula type models; Drug combination.
1 Introduction
Cancer phase I clinical trials constitute the first step in investigating a potentially promising com-
bination of cytotoxic and biological agents. Due to safety and ethical concerns, patients are sequen-
tially enrolled in the trial, and the dose combinations assigned to subsequent patients depend on
dose combinations already given to previous patients and their dose limiting toxicity (DLT) status
at the end of the first cycle of therapy. The main objective of these trials is to estimate a maximum
tolerated dose (MTD) that will be used in future efficacy evaluation in phase II/III trials. The
MTD is usually defined as any dose combination (x, y) that will produce DLT in a prespecified
proportion θ of patients,
Prob(DLT| dose = (x, y)) = θ. (1)
The definition of DLT depends on the type of cancer and drugs under study, but it is usually
defined as a grade 3 or 4 non-hematologic toxicity (see the National Cancer Institute CTCAE
v4.03 for the definition of the different grades of toxicity). The pre-specified proportion of DLTs θ,
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sometimes referred as target probability of DLT, also depends on the nature of the toxicity, but it
usually take values between 0.2 and 0.4.
In the drug combination dose finding literature, designs that recommend a unique MTD (see e.g.
[29, 30, 25, 24, 17, 16, 27, 11]) or multiple MTDs (see e.g. [18, 26, 31, 2, 9, 23, 20, 21]) have been
studied extensively. Most of these methods use a parametric model for the dose-toxicity relationship
Prob(DLT|(x, y)) = F ((x, y), ξ), (2)
where (x, y) represents the drug combination of two agents, F (.) is a known link function, e.g.
a power model or a logistic model, and ξ ∈ Rd is a vector of d unknown parameters. Non-
parametric designs have been proposed in the past, both in single agent and drug combination
settings [9, 6, 28]. These designs unique assumption is monotonicity, which is imposed either
through the prior distribution (see [6, 28]), or by choosing only monotonic contours when escalating
(see [9]).
Let S be the set of all dose combinations available in the trial, and C(ξ) be the set of dose
combinations (x, y) such the probability of DLT equals a target risk of toxicity θ. Hence,
C(ξ) = {(x, y) ∈ S : F ((x, y), ξ) = θ}. (3)
Equation (3) is the traditional definition of MTD set. When S is discrete, following [21], we can
define the MTD as the set of dose combinations (x, y) that satisfy
|F ((x, y), ξ)− θ|≤ δ, (4)
since C(ξ) may be empty, i.e., when the MTD is not in S. The threshold parameter δ, 0 < δ < 1,
is pre-specified after close collaboration with the clinician.
This work is motivated by a cancer phase I trial a clinician at Cedars-Sinai Medical Center is
planning. The trial involves the combination of Taxotere, a known cytotoxic agent, and Metformin,
a diabetes drug, in advanced or metastatic breast cancer patients. According to the clinician, some
DLTs can be attributable to either agent or both. For example, a grade 3 or 4 neutropenia can
only be attributable to Taxotere and not Metformin. Furthermore, for ethical reasons, if a patient
has a DLT attributable to Taxotere when treated with dose level xT of taxotere, then xT cannot
be increased for the next patient in the trial (see the dose escalation restriction in Section 2.2).
Very few methods have been developed to incorporate toxicity attribution in the dose escalation
process. [29] proposed a design that models the joint probability of toxicity with a copula model
known as the Gumbel model [12]. This model allows the investigator to compute the probability
of DLT when the DLT is exclusively attributed to one drug, the other one, or both. However, they
require all toxicities to be attributable, which is rare in practice. [27] proposed a semi-attributable
toxicity design based on a trial with non-concurrent drug administration. In their design, one drug
is administered at the beginning of the treatment cycle and the other drug is administered at a
much later time point if and only if the patient did not experience DLT. If a DLT occurs before
the second drug is administered, then the DLT is attributed to the first drug. However, if the
DLT occurs after the second drug has been administered, then the DLT could be caused by any
of the drugs and therefore is not attributable. [7] propose a method that reduces the effect of the
bias caused by toxicity attribution errors by using personalized scores instead of the traditional
binary DLT outcome. [8] considered the toxicity attribution problem for ruled-based designs with
non-overlapping toxicities.
In this article, we propose a Bayesian adaptive design for drug combinations that allows the
investigator to attribute a DLT to one or both agents in an unknown fraction of patients, even
when the drugs are given concurrently.
We define toxicity attribution as a DLT caused by one drug and not the other when the type
of DLT is non-overlapping, e.g., a grade 4 neutropenia is caused by taxotere but can never occur
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with metformin, or when the clinician judges that a type of DLT is caused by one drug and not the
other, e.g., a grade 4 diarrhea is caused by taxotere but not metformin due to the low dose level of
taxotere that was given in combination even though both drugs have this side effect in common.
The relationship between the dose combinations and the risk of toxicity is modeled using the
same copula model used by [29]. The design proceeds using a variation of the algorithm proposed
in [21] where cohorts of two patients are allocated to dose combinations where, at each stage of the
trial, we search for the dose of one agent given the current dose of the other agent. Our approach
differs from the methodologies of [29] and [21] in three aspects; (i) a non-negative fraction of DLTs
are attributable to either one or both agents, (ii) the dose combination allocated to patients uses
the CRM scheme as opposed to escalation with overdose control (EWOC) approach proposed by
[1], and (iii) if a current patient experiences DLT attributed drug D1 at dose level xD1 , then the
dose level of agent D1 cannot be more than xD1 for the next cohort of two patients. At the end of
the trial, an estimate of the MTD curve is proposed as a function of Bayes estimates of the model
parameters. Last, we show that our method can be easily adapted from a setting with continuous
dose combinations to discrete dose combinations by rounding up the estimated MTD curve to the
nearest discrete dose combinations.
The rest of the manuscript is organized as follows. In Section 2, we describe the model for
the dose-toxicity relationship and the adaptive design to conduct the trial for continuous dose
combinations. In Section 3, we study the performance of the method in terms of safety and efficiency
of the estimate of the MTD set. In Section 4, we adapt our proposal to the setting of discrete
dose combinations. In section 5, we conduct a model misspecification evaluation. Discussion and
practical considerations of the method are discussed in Section 6.
2 Method
2.1 Dose-Toxicity Model
Let Xmin, Xmax, Ymin, Ymax, be the minimum and maximum doses available in a trial that combines
drugs with continuous dose combination levels. The doses are standardized to be in a desired
interval, e.g., [0.05, 0.3], so that Xmin = Ymin = 0.05 and Xmax = Ymax = 0.3. Let Fα(·) and Fβ(·)
be parametric models for the probability of DLT of drugs D1 and D2, respectively. We specify the
joint dose-toxicity relationship using the Gumbel copula model (see [12]) as
pi(δ1,δ2) = Prob(δ1, δ2|x, y) = F δ1α (x) [1− Fα(x)]1−δ1 ×
F δ2β (y) [1− Fβ(y)]1−δ2 + (−1)(δ1+δ2)Fα(x) [1− Fα(x)]Fβ(y) [1− Fβ(y)]
e−γ − 1
e−γ + 1
,
(5)
where x is the standardized dose level of drug D1, y is the standardized dose level of agent D2, δ1 is
the binary indicator of DLT attributed to drug D1, δ2 is the binary indicator of DLT attributed to
drug D2 and γ is the interaction coefficient. We assume that the joint probability of DLT, when one
of the drugs is held constant, is monotonically increasing; that is Prob(DLT|x′, y) ≥ Prob(DLT|x, y)
or Prob(DLT|x, y′) ≥ Prob(DLT|x, y), where x′ > x and y′ > y. A sufficient condition for this
property to hold is to assume that Fα(·) and Fβ(·) are increasing functions with α > 0 and β > 0.
In this article we use Fα(x) = x
α and Fβ(y) = y
β. Using (5), if the DLT is attributed exclusively
to drug D1, then
pi(δ1=1,δ2=0) = Prob(δ1 = 1, δ2 = 0|x, y) = xα(1− yβ)− xα (1− xα) yβ
(
1− yβ) e−γ − 1
e−γ + 1
. (6)
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If the DLT is attributed exclusively to drug D2, then
pi(δ1=0,δ2=1) = Prob(δ1 = 0, δ2 = 1|x, y) = yβ(1− xα)− xα (1− xα) yβ
(
1− yβ) e−γ − 1
e−γ + 1
. (7)
If the DLT is attributed to both drugs D1 and D2, then
pi(δ1=1,δ2=1) = Prob(δ1 = 1, δ2 = 1|x, y) = xαyβ + xα (1− xα) yβ
(
1− yβ) e−γ − 1
e−γ + 1
. (8)
Equation (6) represents the probability that D1 causes a DLT and drug D2 does not cause a DLT.
This can happen, for example, when a type of DLT of taxotere (D1), such as grade 4 neutropenia,
is observed. However, this type of DLT can never be observed with metformin (D2). This can also
happen when the clinician attributes a grade 4 diarrhea to taxotere (D1) but not to metformin (D2)
in the case of a low dose level of this later even though both drugs have this common type of side
effect. The fact that dose level y is present in equation (6) is a result of the joint modeling of the
two marginals and accounts for the probability that drug D2 does not cause a DLT. This later case
is, of course, based on the clinicians judgment. Equations (7) and (8) can be interpreted similarly.
Following [29], it is easy to see that the total probability of having a DLT is calculated as the
sum of (6), (7) and (8). Hence,
pi = Prob(DLT|x, y) = pi(δ1=1,δ2=0) + pi(δ1=0,δ2=1) + pi(δ1=1,δ2=1) =
xα + yβ − xαyβ − xα (1− xα) yβ (1− yβ) e−γ − 1
e−γ + 1
.
(9)
We define the MTD as any dose combination (x∗, y∗) such that Prob(DLT|x∗, y∗) = θ. We set
(9) equal to θ and re-write it as a 2nd degree polynomial in yβ, and solve for the solutions. This
allows us to define the MTD set C(α, β, γ) as
C(α, β, γ) =
(x∗, y∗) : y∗ =
[
−(1− xα∗ − κ)±
√
(1− xα∗ − κ)2 − 4κ(xα∗ − θ)
2κ
] 1
β
 , (10)
where
κ = xα∗ (1− xα∗ )
e−γ − 1
e−γ + 1
.
Let T be the indicator of DLT, T = 1 if a patient treated at dose combination (x, y) experiences
DLT within one cycle of therapy that is due to either drug or both, and T = 0 otherwise. Among
patients treated with dose combination (x, y) who exhibit DLT, suppose that an unknown fraction
η of these patients have a DLT with known attribution, i.e. the clinician knows if the DLT is
caused by drug D1 only, or drug D2 only, or both drugs D1 and D2. Let A be the indicator of
DLT attribution when T = 1. It follows that for each patient treated with dose combination (x, y),
there are five possible toxicity outcomes: {T = 0}, {T = 1, A = 0}, {T = 1, A = 1, δ1 = 1, δ2 =
0}, {T = 1, A = 1, δ1 = 0, δ2 = 1} and {T = 1, A = 1, δ1 = 1, δ2 = 1}. This is illustrated in the
chance tree diagram in Figure 1. Using equations (6),(7),(8),(9) and Figure 1, the contributions
to the likelihood from each of the five observable outcomes are listed in Table 1. The likelihood
function is defined as
L(α, β, γ, η | data) =
n∏
i=1
[(ηpi
(δ1i ,δ2i )
i )
Ai(pii (1− η))1−Ai ]Ti(1− pii)1−Ti , (11)
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and the joint posterior probability distribution of the model parameters as
Prob(α, β, γ, η | data) ∝ Prob(α, β, γ)× L(α, β, γ | data). (12)
With equation (12) we can easily sample and obtain MCMC estimates of α, β, γ and η.
Figure 1: A chance tree illustrating the five possible outcomes we can find in a trial.
Table 1: Contributions to the likelihood function based on the observed outcomes: toxicity, attri-
bution, attribution to drug 1 (δ1) and attribution to drug 2 (δ2) for each patient.
Toxicity Attribution δ1 δ2 Likelihood
0 - - - 1− pi = 1− [xα + yβ − xα × yβ− xα (1− xα) yβ (1− yβ) e−γ−1
e−γ+1 ]
1 0 - - pi × (1− η) = [xα + yβ − xα × yβ− xα (1− xα) yβ (1− yβ) e−γ−1
e−γ+1 ]× (1− η)
1 1 1 0 pi × η × pi(1,0)
pi
= η × [xα(1− yβ)− xα (1− xα) yβ (1− yβ) e−γ−1
e−γ+1 ]
1 1 0 1 pi × η × pi(0,1)
pi
= η × [yβ(1− xα)− xα (1− xα) yβ (1− yβ) e−γ−1
e−γ+1 ]
1 1 1 1 pi × η × pi(1,1)
pi
= η × [xα × yβ+ xα (1− xα) yβ (1− yβ) e−γ−1
e−γ+1 ]
2.2 Trial Design
Dose escalation / de-escalation proceeds using the algorithm described in [21] but univariate con-
tinual reassessment method (CRM) is carried out to estimate the next dose instead of EWOC.
In a cohort with two patients, the first one would receive a new dose of agent D1 given the dose
y of agent D2 that was previously assigned. The new dose of agent D1 is defined as xnew =
argminu|P̂rob(DLT|u, y) − θ|,where y is fixed and ˆProb(DLT|u, y) is computed using equation (9)
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with α, β, γ replaced by their posterior medians. The other patient would receive a new dose of
agent D2 given the dose of agent D1 that was previously assigned. Specifically, the design proceeds
as follows:
1. Patients in the first cohort receive the same dose combination (x1, y1) = (x2, y2) = (Xmin, Ymin).
2. In the i-th cohort of two patients,
• If i is even,
– Patient (2i−1) receives doses (x2i−1, y2i−1), where x2i−1 = argmin
u
∣∣∣P̂rob(DLT|u, y2i−3)− θ∣∣∣ ,
and y2i−1 = y2i−3. If a DLT was observed in the previous cohort of two patients and
was attributable to drug D1, then x2i−1 is further restricted to be no more than
x2i−3.
– Patient 2i receives doses (x2i, y2i), where y2i = argmin
v
∣∣∣P̂rob(DLT|x2i−2, v)− θ∣∣∣ , and
x2i = x2i−2. If a DLT was observed in the previous cohort of two patients and was
attributable to drug D2, then y2i is further restricted to be no more than y2i−2.
• If i is odd,
– Patient (2i−1) receives doses (x2i−1, y2i−1), where y2i−1 = argmin
v
∣∣∣P̂rob(DLT|x2i−3, v)− θ∣∣∣ ,
and x2i−1 = x2i−3. If a DLT was observed in the previous cohort of two patients
and was attributable to drug D2, then y2i−1 is further restricted to be no more than
y2i−3.
– Patient 2i receives doses (x2i, y2i), where x2i = argmin
u
∣∣∣P̂rob(DLT|u, y2i−2)− θ∣∣∣ , and
y2i = y2i−2. If a DLT was observed in the previous cohort of two patients and was
attributable to drug D1, then x2i is further restricted to be no more than x2i−2.
3. Repeat step 2 until the maximum sample size is reached subject to the following stopping
rule.
4. We would stop the trial if, Prob(Prob(DLT|x = Xmin, y = Ymin) ≥ θ+ξ1|data) > ξ2, i.e. if the
posterior risk of toxicity at the lowest combination significantly is high. ξ1 and ξ2 are design
parameters tuned to obtain the best operating characteristics.
In step 2 of the algorithm, any dose escalation is further restricted to be no more than a pre-
specified fraction of the dose range of the corresponding agent. At the end of the trial, we obtain the
MTD curve estimate Cˆ = C(αˆ, βˆ, γˆ), where αˆ, βˆ and γˆ are the posterior medians of the parameters
α, β and γ, given the data.
3 Simulation Studies
3.1 Simulation set up and Scenarios
In all simulated trials, the link functions Fα(x) = x
α and Fβ(y) = y
β are used. To evaluate the
performance of our proposal, the DLT outcomes are generated from the true model showed in (9).
We used this model in 3 different scenarios to study the behavior of our design when the prior
distribution of the model parameters is both well and poorly calibrated. Let αtrue, βtrue and γtrue
represent the true parameter values we use in (9) to generate DLT outcomes. In each scenario we
select different values for αtrue, βtrue, but the prior distribution for α and β, P (α) and P (β), as well
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as γtrue, do not vary. In scenario 1, we choose values for αtrue and βtrue such that αtrue < E[P (α)] and
βtrue < E[P (β)]. In scenario 2, we choose values for αtrue and βtrue such that αtrue = E[P (α)] and
βtrue = E[P (β)]. Last, in scenario 3, we choose values for αtrue and βtrue such that αtrue > E[P (α)]
and βtrue > E[P (β)]. Figure 2 shows the MTD curves with the true parameter values described
here and their contours at θ ± 0.05 and θ ± 0.1. We evaluate the effect of toxicity attribution in
these 3 scenarios using 4 different values for η: 0, 0.1, 0.25 and 0.4. These values are reasonable
because higher values of η in practice are very rare. Data is randomly generated using the following
procedure:
• For a given dose combination (x, y), a binary indicator of DLT T is generated from a Bernoulli
distribution with probability of success computed using equation (9).
• If {T = 1}, we generate the attribution outcome A using a Bernoulli distribution with prob-
ability of success η.
• If {T = 1, A = 1}, we attribute the DLT to drug D1, D2, or to both drugs with equal
probabilities.
We assume that the model parameters α, β, γ and η are independent a priori. We assign vague
prior distributions to α, β and γ following [29], where α ∼ Uniform(0.2, 2), β ∼ Uniform(0.2, 2) and
γ ∼ Gamma(0.1, 0.1). These prior distributions correspond to the ones used by [29] for the main
analysis. The prior distribution for the fraction of attributable toxicities η is set to be Uniform(0, 1).
With these prior distributions, the true parameter values for each scenario are as follows. In scenario
1, α = β = 0.9 and γ = 1. In scenario 2, α = β = 1.1 and γ = 1. Last, in scenario 3, α = β = 1.3
and γ = 1. For each scenario, m = 1000 trials will be simulated. The target risk of toxicity is fixed
at θ = 0.3, the sample size is n = 40, and the values for ξ1 and ξ2 will be 0.05 and 0.8 respectively.
All simulation are done using the software R version 3.3.1.
Figure 2: Contour plots for the working model in scenarios 1, 2 and 3. The black dashed curve
represents the true MTD curve and the gray dashed lines represent the contours at θ ± 0.05 and
θ ± 0.10.
3.2 Design Operating Characteristics
We evaluate the performance of the design by assessing its safety and its efficiency in estimating
the MTD curve.
For trial safety, we employ the average percent of DLTs, the percent of simulated trials with
DLT rate greater than θ ± 0.05 and θ ± 0.10.
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For efficiency, we employ the pointwise average relative minimum distance from the true MTD
curve to the estimated MTD curve. This measure of efficiency is well described in [23, 21] and can
interpreted as a pointwise average bias in estimating the true MTD curve. We also consider the
pointwise percent of trials for which the minimum distance of the point (x, y) on the true MTD
curve to the estimated MTD curve is no more than (100 × p)% of the true MTD curve. This
measurement will give us an estimate of the percent of trials with MTD recommendation within
(100 p)% of the true MTD. This measure of efficiency can be interpreted as the pointwise percent
of correct MTD recommendation. In this paper we select p = 0.1, 0.2. For a detailed explanation
of these measures of efficiency, see [23, 21].
3.3 Results
In general, increasing the value of η until 0.4 generates estimated MTD curves closer to the true
MTD curve. Figure 3 shows the estimated MTD curves for each scenario as a function of η. In
terms of safety, overall we observe that increasing the fraction of toxicity attributions η reduces
the average percent of toxicities and percent of trials with toxicity rates greater than θ + 0.05 and
θ+0.10. Table 2, shows the average percent of toxicities as well as the percent of trials with toxicity
rates greater than θ + 0.05 and θ + 0.1 for scenarios 1-3.
Figure 4 shows the pointwise average bias of the 3 proposed scenarios for each value of η.
Overall, increasing the value of η until 0.4 reduces the pointwise average bias. In any case, the
pointwise average bias is around 10% of the dose range of either drug and practically negligible for
η = 0.25, 0.4. For instance, under scenario 3, the maximum absolute value of the pointwise average
bias when η = 0.40 is about 0.01, which corresponds to 0.3% of the dose range, which is practically
negligible.
Figure 5 shows the pointwise percent of MTD recommendation of the 3 proposed scenarios
for each value of η. In general, increasing the value of η increases the pointwise percent of MTD
recommendation, reaching up to 80% of correct recommendation when p = 0.2, and up to 70%
of correct recommendation when p = 0.1. Based on these simulation results, we conclude that in
continuous dose setting the approach of partial toxicity attribution generates safe trial designs and
efficient estimation of the MTD.
Table 2: Operating characteristics summarizing trial safety in m = 1000 simulated trials.
Average
% of toxicities
% of trials with
toxicity rate > θ + 0.05
% of trials with
toxicity rate > θ + 0.10
Scenario 1
η = 0.00 33.62 25.90 4.10
η = 0.10 32.67 22.60 4.80
η = 0.25 31.55 17.60 2.70
η = 0.40 30.70 13.30 2.00
Scenario 2
η = 0.00 30.64 9.40 0.90
η = 0.10 29.69 7.30 0.40
η = 0.25 28.76 5.00 0.20
η = 0.40 28.04 4.10 0.30
Scenario 3
η = 0.00 27.47 2.00 0.00
η = 0.10 26.80 1.80 0.00
η = 0.25 25.99 1.30 0.00
η = 0.40 25.37 0.70 0.00
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Figure 3: Estimated MTD curves for m = 1000 simulated trials. The black dashed curve represents
the true MTD curve, the gray dashed lines represent the contours at θ± 0.05 and θ± 0.10, and the
solid curves represent the estimated MTD curves at each value of η.
Figure 4: Pointwise average bias in estimating the true MTD in m = 1000 simulated trials.
Figure 5: Pointwise percent of MTD recommendation for m = 1000 simulated trials. Solid lines
represent the pointwise percent of MTD recommendation when p = 0.2 and dashed lines represent
the pointwise percent of MTD recommendation when p = 0.1.
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4 Discrete Dose Combinations
4.1 Approach
Dose escalation follows the same procedure described in section 2.2. The only difference is that,
in step 2, the continuous doses recommended are rounded to the nearest discrete dose level. For a
detailed explanation of this procedure see [21].
4.2 Illustration
We study the performance of our proposal in a discrete dose level setting where the probability of
toxicity of each dose level is generated from the working model. We employ 6 scenarios with 4 dose
levels respectively in each drug for scenarios 1 - 3, and 4 and 6 dose levels respectively in each drug
for scenarios 4 - 6. The target probability of toxicity is always θ = 0.3 and, for each scenario, we
simulate m = 1000 trials using the same vague priors for α, β and γ specified in section 3.1. The
maximum sample size in all scenarios is again n = 40. The performance of the method is evaluated
using the percent of MTD selection statistic proposed by [21].
In Table 3 we present the 6 mentioned scenarios we use to illustrate the implementation of our
design with discrete dose levels. Moreover, in Figure 6 we show the dose-toxicity surface of these 6
scenarios, where we observe that all of them have a flat (near-constant) surface.
Figure 6: Probability of DLT surfaces of the 6 scenarios from Table 3.
In Table 4 we show the percent of times that at least 25%, 50%, 75% or 100% of recommended
MTDs belong to the true MTD set. Using vague prior distributions, the scenario where toxicity
attribution has the strongest effect is scenario 2. In scenarios 1,4 and 5, we observe a slight effect
but it does not make a big difference.
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Table 3: Dose limiting toxicity scenarios with θ = 0.3 generated with the working model. In bold
the dose combination levels that would compose the true MTD set.
Dose level 1 2 3 4 1 2 3 4 5 6
Scenario 1 Scenario 4
4 0.39 0.46 0.52 0.58 0.39 0.43 0.47 0.51 0.55 0.58
3 0.31 0.38 0.46 0.52 0.30 0.35 0.40 0.44 0.48 0.52
2 0.22 0.31 0.38 0.46 0.22 0.27 0.32 0.37 0.41 0.46
1 0.13 0.22 0.31 0.39 0.13 0.19 0.24 0.29 0.34 0.39
Scenario 2 Scenario 5
4 0.30 0.36 0.42 0.48 0.30 0.33 0.37 0.40 0.44 0.48
3 0.22 0.28 0.35 0.42 0.22 0.26 0.29 0.33 0.38 0.42
2 0.14 0.21 0.28 0.36 0.14 0.18 0.22 0.27 0.31 0.35
1 0.07 0.14 0.22 0.30 0.07 0.11 0.16 0.20 0.25 0.30
Scenario 3 Scenario 6
4 0.23 0.27 0.33 0.39 0.23 0.25 0.28 0.32 0.35 0.39
3 0.16 0.21 0.26 0.33 0.16 0.18 0.22 0.25 0.29 0.33
2 0.09 0.14 0.21 0.27 0.09 0.12 0.16 0.19 0.23 0.27
1 0.04 0.09 0.16 0.23 0.04 0.07 0.11 0.14 0.19 0.23
Table 4: Percent of times that at least 25%, 50%, 75% or 100% of recommended MTDs belong to
the true MTD set in m = 1000 simulated trials.
% of correct MTD recommendation for θ ± 0.10
≥ 25% ≥ 50% ≥ 75% 100% ≥ 25% ≥ 50% ≥ 75% 100%
η = 0.00
Scenario 1
91.40 87.30 83.70 83.70
Scenario 4
90.00 85.50 73.70 67.70
η = 0.10 92.50 87.80 83.90 83.90 91.30 86.00 71.10 65.80
η = 0.25 90.90 87.70 83.80 83.80 89.40 85.90 71.50 68.20
η = 0.40 90.90 87.70 83.80 83.80 89.80 85.70 70.50 67.30
η = 0.00
Scenario 2
78.10 78.10 73.60 73.60
Scenario 5
82.90 81.50 72.70 72.70
η = 0.10 79.80 79.80 73.90 73.90 82.80 81.40 71.70 71.70
η = 0.25 83.00 83.00 75.50 75.50 85.00 81.80 71.00 71.00
η = 0.40 83.50 83.50 76.20 76.20 85.70 82.50 70.60 70.60
η = 0.00
Scenario 3
99.10 99.00 97.00 97.00
Scenario 6
98.80 96.50 93.10 92.70
η = 0.10 99.30 98.60 95.10 95.10 98.60 95.70 89.90 89.60
η = 0.25 97.10 96.40 91.90 91.90 96.20 92.10 87.00 86.20
η = 0.40 95.90 95.10 89.50 89.50 94.00 89.50 81.90 81.00
5 Model Misspecification
In the previous sections, all the simulated scenarios are generated with the model showed in (9).
However, in practice we do not know the underlying model that generates the data and therefore
we need to assess the performance of our design under model misspecification. We employ the same
toxicity scenarios used by [29], which are shown in Table 5. Moreover, In Figure 7 we show the
dose-toxicity surface of these scenarios. Scenario 1 presents a very constant surface gradient. The
rest of the scenarios present surface gradients that vary as we increase the dose combination levels.
However, scenarios 3, 4 and 6 vary more abruptly than scenarios 2 and 5. Scenario 6 is a particular
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Table 5: Toxicity scenarios for the model misspecification evaluation. In bold the doses considered
as true MTD set.
Dose level 1 2 3 4 1 2 3 4
Scenario 1 Scenario 4
4 0.28 0.41 0.55 0.68 0.04 0.09 0.17 0.32
3 0.25 0.35 0.48 0.60 0.03 0.06 0.12 0.23
2 0.22 0.30 0.40 0.51 0.02 0.05 0.09 0.16
1 0.19 0.26 0.34 0.43 0.02 0.03 0.06 0.11
Scenario 2 Scenario 5
4 0.17 0.29 0.45 0.62 0.12 0.26 0.48 0.71
3 0.14 0.23 0.35 0.50 0.09 0.19 0.36 0.57
2 0.12 0.18 0.27 0.38 0.07 0.14 0.26 0.43
1 0.09 0.14 0.19 0.27 0.05 0.10 0.18 0.30
Scenario 3 Scenario 6
4 0.37 0.72 0.92 0.98 0.78 0.94 0.99 1.00
3 0.26 0.59 0.85 0.96 0.68 0.90 0.97 0.99
2 0.18 0.44 0.74 0.91 0.57 0.83 0.94 0.98
1 0.12 0.30 0.59 0.82 0.45 0.73 0.90 0.97
case because the lowest dose combination level has a probability of DLT that is already higher than
the target risk of toxicity θ + 0.1. Therefore, for this scenario, instead of presenting the percent of
correct recommendation we present the percent of times the trial is stopped due to safety using the
stopping rule in Section 2.2 with ξ1 = 0.05 and ξ2 = 0.8. For each scenario, we simulate m = 1000
trials with a target risk of toxicity of θ = 0.30, a sample size of n = 40 and we use the same prior
distributions for α, β and γ as in section 3.1.
Figure 7: Probability of DLT surfaces of the 6 scenarios from Table 5.
In terms of safety, in general we observe that toxicity attributions reduce the average percent
of toxicities and percent of trials with toxicity rates greater than θ + 0.05 and θ + 0.10. Table 6
shows the average percent of toxicities as well as the percent of trials with toxicity rates greater
than θ + 0.05 and θ + 0.1.
In Table 7, we show the percent of times that at least 25%, 50%, 75% or 100% of recommended
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MTDs belong to the true MTD set. In scenario 1 we observe a positive effect of the toxicity
attributions, improving the percent of times at least 75% and 100% of recommended MTDs belong
to the true MTD set in to 5% when η = 0.25. In scenario 2 we observe a positive effect of the
toxicity attributions improving the percent of times at least 25% and 50% of recommended MTDs
belong to the true MTD up to 5% and 4% respectively. In scenarios 3, 4 and 5 we do not observe
any positive effect when attributing toxicities. However, these scenarios are particularly difficult
for our design given the rounding up procedure we follow with discrete dose combinations. In
scenario 6 we observe a positive effect of the toxicity attributions, improving the percent of times
the trial is stopped due to safety by almost 4% when η = 0.40. Based on these simulation results
under model misspecification, we conclude that the partial toxicity attribution method has good
operating characteristics in recommending dose combinations of which, at least 50% are the true
MTDs; these percent of correct recommendations vary between 65% to 98% depending on the
scenario. Moreover, there is a high probability of stopping the trial if there is evidence that the
minimum dose combination in the trial has high probability of DLT.
However some of the scenarios showed in Table 5 have a true set of MTDs that include a large
number of dose combinations. For this reason, we implemented our design in 6 extra scenarios taken
from [29, 30]. These scenarios are presented in Table S1 at the supplementary material, where the
set of true MTDs contains a much more restricted number of dose combinations. Also, since the
scenarios showed in Table 5 where generated with a logistic model, we selected the scenarios to
observe how robust is our proposal in scenarios generated with other models, such us the Clayton
Copula, and scenarios that are arbitrarily generated. Moreover, since we are using the same set of
true MTDs as [29, 30], we use these methods to make a performance comparison in terms of percent
of correct MTD selection.
In Tables S2 and S3, in the supplementary material, we present operating characteristics in term
of safety and efficiency for each of the 6 proposed scenarios. In general, we observe that the design
behaves in a similar way as with the scenarios presented along this manuscript. In terms of safety,
toxicity attributions reduce the average percent of toxicities and the percent of trials with toxicity
rates greater than θ + 0.05 and θ + 0.10. In terms of efficiency, we only observe a positive effect
in scenarios with a relatively flat dose-toxicity surface. In terms of performance comparison, our
proposed method is competitive with other standard designs for drug combinations such us [29, 30],
and achieves better percent of correct MTD recommendation in 4 out of the 6 used scenarios.
Another issue that is relevant to the methodology we present in this manuscript is the errors in
the attribution of toxicities by the treating investigators. Our design does not include a parameter
to control the uncertainty around the decision made by the investigator when attributing the the
DLT, which could be an extension of this work. However, in the supplementary material, in order
to assess the impact of these kind of errors, we present simulation from 3 scenarios taken also from
[29, 30] where we introduce 10% and 50% of errors in the attribution of DLTs, and compare it to
the case where we correctly attributes 100% of the DLTs. In Tables S4 and S5, we present the
simulated results in terms of safety and efficiency. Overall we do not observe any major difference
when incorrectly attributing 10% and 50% of the DLTs with respect to correctly attributing 100%
of the DLTs.
6 Conclusions
In this paper we proposed a Bayesian adaptive design for cancer phase I clinical trials using drug
combinations with continuous dose levels and attributable DLT in a fraction of patients. A copula-
type model was used to describe the relationship between dose combinations and probability of
DLT. The trial design proceeds by treating cohorts of two patients, each patient with a different
dose combination estimated using univariate CRM for a better exploration of the space of doses.
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Table 6: Operating characteristics summarizing trial safety for model misspecification in m = 1000
simulated trials.
Average
% of toxicities
% of trials with
toxicity rate > θ + 0.05
% of trials with
toxicity rate > θ + 0.10
Scenario 1
η = 0.00 32.99 22.90 4.20
η = 0.10 32.19 18.50 2.90
η = 0.25 31.43 15.80 2.60
η = 0.40 30.58 12.90 2.50
Scenario 2
η = 0.00 29.85 6.60 0.20
η = 0.10 29.14 4.10 0.10
η = 0.25 28.20 3.10 0.30
η = 0.40 27.90 2.30 0.00
Scenario 3
η = 0.00 36.53 40.70 16.40
η = 0.10 35.13 33.90 12.50
η = 0.25 33.94 28.60 11.00
η = 0.40 32.94 23.40 9.50
Scenario 4
η = 0.00 22.43 0.00 0.00
η = 0.10 21.83 0.00 0.00
η = 0.25 21.39 0.00 0.00
η = 0.40 20.87 0.00 0.00
Scenario 5
η = 0.00 30.43 6.60 0.30
η = 0.10 29.48 3.30 0.10
η = 0.25 28.60 3.60 0.00
η = 0.40 27.60 2.30 0.00
Treating cohorts of two patients will allow trial conduct to be completed in a reasonable amount
of time. Although the two patients in a cohort are allocated to different dose combinations, a
patient in the current cohort can be treated at a dose (x, y) if and only if a patient in the previous
cohort was treated at a dose on the same horizontal or vertical line within our dose range, that is
was treated with either dose x or dose y. The use of continuous dose levels is not uncommon in
early phase trials, particularly when the drugs are given as infusions intravenously. For instance,
a drug combination trial of cabazitaxel and cisplatin delivered intravenously was recently designed
for advanced prostate cancer patients where the dose levels are continuous and the protocol was
approved by the scientific review at Cedars-Sinai. For ethical reasons, we further imposed dose
escalation restrictions for one of the drugs when a DLT is attributable to that drug.
We studied the operating characteristics of the design under various scenarios for the true
location of the MTD curve. In general, we observed that the trial is safe and as the proportion
of attributed toxicities increases, the average proportion of toxicities decreases when we attribute
toxicities. To assess the efficiency when estimating the MTD curve, we employed the pointwise
average bias and average percent selection. In general the method is efficient although the results
varied depending on the proportion of attributed toxicities. Note that the operating characteristics
were evaluated under vague prior distributions of the model parameters and no toxicity profiles
of single agent trials were used a priori. We also showed how the method can be adapted to the
setting of discrete dose combinations.
We also performed a model misspecification evaluation in scenarios with different dose-toxicity
surfaces. We only observed a positive effect in terms of percent of correct MTD recommendation in
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Table 7: Percent of times that at least 25%, 50%, 75% or 100% of recommended MTDs belong to
the true MTD set in m = 1000 simulated trials under model misspecification. In scenario 6 we
show the percent of times the trial is stopped due to safety reasons.
% of correct MTD recommendation for θ ± 0.10
≥ 25% ≥ 50% ≥ 75% 100% ≥ 25% ≥ 50% ≥ 75% 100%
η = 0.00
Scenario 1
82.90 75.60 55.40 55.40
Scenario 4
98.80 98.80 87.80 87.80
η = 0.10 82.70 72.70 57.30 57.30 97.20 97.20 85.70 85.70
η = 0.25 83.30 75.80 60.40 60.40 95.70 95.70 82.00 82.00
η = 0.40 80.60 73.10 57.60 57.60 95.20 95.20 76.20 76.20
η = 0.00
Scenario 2
74.70 71.00 58.20 45.70
Scenario 5
75.40 69.10 20.50 20.50
η = 0.10 77.00 73.50 53.60 44.60 71.80 62.80 20.40 20.40
η = 0.25 79.60 75.00 50.00 41.20 70.70 59.40 18.90 18.90
η = 0.40 77.30 73.10 47.90 37.80 71.20 60.50 16.70 16.70
η = 0.00
Scenario 3
76.90 65.30 23.30 23.30
Scenario 6
83.60
η = 0.10 72.50 61.80 21.90 21.90 82.90
η = 0.25 66.40 57.30 18.60 18.60 84.80
η = 0.40 66.10 54.70 15.70 15.70 87.20
scenarios with flat surfaces. In scenarios with non-flat dose-toxicity surfaces we observed a decline
in performance of percent selection consistent with the findings by [16] when working with copula
regression models. We also observed a positive effect in scenarios where the lowest dose combination
has an excessively high probability of DLT. In this case, toxicity attributions improves the percent
of times the trial was stopped due to safety. In all cases, safety of the trial is not compromised by
accounting for a partial toxicity attribution. Clearly, there is a trade-off when increasing the fraction
of DLT attribution to one or more drugs. The design is more conservative in future escalations,
lowering the in-trial DLT percentages and reducing how quickly the MTD contour is reached, by
favoring experimentation over recommendation.
Our design is practically useful when the two drugs do not have many overlapping toxicities,
see e.g. [10] for some examples of drug combination trials with these characteristics. In cases
where we expect a high percent of overlapping DLTs, designs that do not distinguish between
drug attribution listed in the introduction may be more appropriate. Our method relies on clinical
judgment regarding DLT attribution. In many phase I trials, such decisions are subject to error
classifications and a possible extension is to introduce a parameter to account for errors in toxicity
attribution as in [7] for single agent trials. We also plan to study the performance of this design using
other link functions under different copula models, and extend this method to early phase cancer
trials with late onset toxicity and by accounting for patient’s baseline characteristic by extending
the approaches in [22, 19] to the drug combination setting.
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